This study was funded by National Institutes of Health grants R01HL105826 and K02HL114749 (Dr. Sadayappan), and American Heart Association Midwest Fellowships; 11PRE7240022 (Mr. Barefield) and 13POST14720024 (Dr. Govindan). The authors gratefully acknowledge the assistance of Dr. Jimmy Page, Jill Clampit and Dr. John Hudson, MSD, for their excellent technical and literature support in developing the assay.

1. Uniplex cMyBP-C Assay
<ol>
	<li>The day before the experiment, coat the 96-well MSD bare standard plate with capture antibody. For cMyBP-C, use a 30 &mu;l volume of mouse monoclonal anti-cMyBP-C antibody (gelatin free) at a concentration of 5 &mu;g/ml diluted in phosphate buffered saline (PBS).</li>
	<li>Since the well is hydrophobic, pipette the solution into the bottom corner of the well; then tap the sides of the plate to spread the solution over the entire well.</li>
	<li>The plate is covered with a plate sealer...

<ol>
	<li>Thygesen, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Third+universal+definition+of+myocardial+infarction.">Third universal definition of myocardial infarction.</a> Eur. Heart J. 33, 2551-2567 (2012).</li><li>Leng, S. X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=ELISA+and+multiplex+technologies+for+cytokine+measurement+in+inflammation+and+aging+research.">ELISA and multiplex technologies for cytokine measurement in inflammation and aging research.</a> J. Gerontol. A. Biol. Sci. Med. Sci. 63, 879-884 (2008).</li><li>Thompson, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Competitive+electrochemiluminescence+wash+and+no-wash+immunoassays+for+detection+of+serum+antibodies+to+smooth+Brucella+strains.">Competitive electrochemiluminescence wash and no-wash immunoassays for detection of serum antibodies to smooth Brucella strains.</a> Clin. Vaccine Immunol. 16, 765-771 (2009).</li><li>Kingsmore, S. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Multiplexed+protein+measurement:+technologies+and+applications+of+protein+and+antibody+arrays.">Multiplexed protein measurement: technologies and applications of protein and antibody arrays.</a> Nat. Rev. Drug. Discov. 5, 310-320 (2006).</li><li>Altan, Z. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+long-acting+tumor+necrosis+factor+alpha-binding+protein+demonstrates+activity+in+both+in+vitro+and+in+vivo+models+of+endometriosis.">A long-acting tumor necrosis factor alpha-binding protein demonstrates activity in both in vitro and in vivo models of endometriosis.</a> J. Pharmacol. Exp. Ther. 334, 460-466 (2010).</li><li>Patel, K. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=High+sensitivity+cytokine+detection+in+acute+coronary+syndrome+reveals+up-regulation+of+interferon+gamma+and+interleukin-10+post+myocardial+infarction.">High sensitivity cytokine detection in acute coronary syndrome reveals up-regulation of interferon gamma and interleukin-10 post myocardial infarction.</a> Clin. Immunol. 133, 251-256 (2009).</li><li>Fu, Q., Zhu, J., Van Eyk, J. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Comparison+of+multiplex+immunoassay+platforms.">Comparison of multiplex immunoassay platforms.</a> Clin. Chem. 56, 314-318 (2010).</li><li>Mahajan, V. S., Jarolim, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=How+to+interpret+elevated+cardiac+troponin+levels.">How to interpret elevated cardiac troponin levels.</a> Circulation. 124, 2350-2354 (2011).</li><li>Govindan, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cardiac+myosin+binding+protein-C+is+a+potential+diagnostic+biomarker+for+myocardial+infarction.">Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction.</a> J. Mol. Cell Cardiol. 52, 154-164 (2012).</li><li>Barefield, D., Sadayappan, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phosphorylation+and+function+of+cardiac+myosin+binding+protein-C+in+health+and+disease.">Phosphorylation and function of cardiac myosin binding protein-C in health and disease.</a> J. Mol. Cell Cardiol. 48, 866-875 (2010).</li><li>Kuster, D. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cardiac+myosin+binding+protein+C+phosphorylation+in+cardiac+disease.">Cardiac myosin binding protein C phosphorylation in cardiac disease.</a> J. Muscle Res. Cell Motil. 33, 43-52 (2012).</li><li>Sadayappan, S., de Tombe, P. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cardiac+myosin+binding+protein-C:+redefining+its+structure+and+function.">Cardiac myosin binding protein-C: redefining its structure and function.</a> Biophys. Rev. 4, 93-106 (2012).</li><li>Sadayappan, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cardiac+myosin+binding+protein-C:+a+potential+early-stage,+cardiac-specific+biomarker+of+ischemia-reperfusion+injury.">Cardiac myosin binding protein-C: a potential early-stage, cardiac-specific biomarker of ischemia-reperfusion injury.</a> Biomark Med. 6, 69-72 (2012).</li><li>Fichorova, R. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Biological+and+technical+variables+affecting+immunoassay+recovery+of+cytokines+from+human+serum+and+simulated+vaginal+fluid:+a+multicenter+study.">Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study.</a> Anal. Chem. 80, 4741-4751 (2008).</li><li>Malekzadeh, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Challenges+in+multi-plex+and+mono-plex+platforms+for+the+discovery+of+inflammatory+profiles+in+neurodegenerative+diseases.">Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases.</a> Methods. 56, 508-513 (2012).</li></ol>

A full patent application is pending (Application Serial No. 13/464,466, Pub. No. US 2012/0282618 A1 and Date: 05/04/12) to determine the risk factors associated with cMyBP-C degradation and release into human body fluid and quantitate the level of cMyBP-C in human body fluid.

In this study, we show the applicability of a multiplex immunoassay for the detection of multiple cardiac biomarkers in serum from patients. This technique has numerous advantages over traditional ELISA. First, ECL in the assay kit is used instead of colorimetric detection. In ECL, an electrical signal stimulates the local production of the measured property (light), thus uncoupling the stimulation event from the signal, which reduces background14. This allows for high sensitivity, as can be seen in Ta...

The measurement of low amounts of protein in complex biological samples, such as serum, is of growing clinical importance for patient management, as well as basic science. For instance, an increase in serum levels of cardiac biomarkers, such as troponin I, in a clinical setting is consistent with acute myocardial infarction (MI)1. To detect proteins in serum samples, standard enzyme-linked immunosorbent assay (ELISA) is the most often used technique as it has high sensitivity and allows for absolute quantification of the analyte. However, traditional ELISAs require a relatively large amount of sample (typically 100 &mu;l), have high background signal in some biological fluids, and are restricted to the measurement of only one analyte per ELISA2.	
Recently, a new immunoassay technique was introduced that circumvents many of these drawbacks. This modified assay, developed by MSD, uses electrochemiluminescence (ECL) for signal detection, which allows for a very low background and an increased sensitivity, enabling the use of small sample volumes. Electrochemiluminescence is based on the reporter molecule ruthenium (II) trisbipyridal, which is attached to the detection antibodies. This reporter molecule emits light at 620 nm upon the electrical stimulation of the bottom of the 96-well plate which has carbon electrodes integrated in them3. Also, by using spot coating, multiple capture antibodies can be coated into one well (up to 10 on a 96-well plate), allowing for simultaneous quantification of different proteins in a single sample4. This technique has recently been used to measure proinflammatory cytokine profiles in serum5,6. The multiplex plates from MSD compare favorably to other multiplex assay platforms7.
Using MSD as the primary assay platform, we further developed a custom made 3-plex plate that can simultaneously quantify the level of cardiac myosin binding protein-C (cMyBP-C), creatine-kinase MB (CK-MB), and cardiac troponin I (cTnI), and the results were compared with monoplex detection of cMyBP-C. CK-MB and cTnI are well-established biomarkers for MI. However, increases of these biomarkers can be caused by pathologies other than MI, e.g. myocarditis or renal failure8. This argues for the addition of additional biomarkers to increase the specificity of MI diagnosis. We have recently shown that cMyBP-C is also a potential biomarker for MI9. cMyBP-C is a thick filament associated protein that is expressed in the heart,10-12 but not in skeletal or smooth muscles. Thus, the increased level of cMyBP-C in the circulatory system is a specific indicator of cardiac damage13.
In this study, we compared uniplex detection of cMyBP-C with the use of a custom 3-plex assay to measure serum levels of cMyBP-C, CK-MB, and cTnI in serum of patients with MI. In the future, this signature technique might be used to diagnose MI in patients presenting with chest pain in the emergency room.
The institution review board (IRB) of the Loyola University Chicago approved the study for use of deidentified human samples and the use of the immunoassay (LU# 20392).

<table border="1">
	<tbody>
		<tr>
			<td></td>
			<td></td>
			<td></td>
			<td>Reagents</td>
		</tr>
		<tr>
			<td>MSD Read-Buffer T (4X) with surfactant</td>
			<td>Meso Scale Discovery</td>
			<td>R92TC-2</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Tween-20</td>
			<td>Acros</td>
			<td>9005-64-5</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>MSD Blocker A</td>
			<td>Meso Scale Discovery</td>
			<td>R93BA-1</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Phosphate buffered saline, 10X</td>
			<td>Fisher BioReagents</td>
			<td>BP399-4</td>
			<td>Filter before use</td>
		</tr>
		<tr>
			<td>Myosin binding protein C antibody, mouse monoclonal (E7), gelatin free</td>
			<td>Santa Cruz</td>
			<td>SC-137180L</td>
			<td>For coating, antibody has to be gelatin free</td>
		</tr>
		<tr>
			<td></td>
			<td></td>
			<td></td>
			<td>Plates and Equipment</td>
		</tr>
		<tr>
			<td>Multi-Array 96-well standard plate</td>
			<td>Meso Scale Discovery</td>
			<td>L15XA-3</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>A prototype 3-plex, four-spot, 96-well plate with cMyBP-C, cTnI and CK-MB</td>
			<td>Meso Scale Discovery</td>
			<td>N452A-1</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>ThermaSeal Sealing Film</td>
			<td>Life Science Products Inc.</td>
			<td>ST-3098</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>MSD SECTOR Imager 2400A</td>
			<td>Meso Scale Discovery</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>MTS 2/4 digital microtiter shaker</td>
			<td>IKA</td>
			<td>3208001</td>
			<td>&nbsp;</td>
		</tr>
	</tbody>
</table>

a sensitive and specific quantitation method for determination of serum cardiac myosin binding protein-c by electrochemiluminescence immunoassay

Biomarkers are becoming increasingly more important in clinical decision-making, as well as basic science. Diagnosing myocardial infarction (MI) is largely driven by detecting cardiac-specific proteins in patients' serum or plasma as an indicator of myocardial injury. Having recently shown that cardiac myosin binding protein-C (cMyBP-C) is detectable in the serum after MI, we have proposed it as a potential biomarker for MI. Biomarkers are typically detected by traditional sandwich enzyme-linked immunosorbent assays. However, this technique requires a large sample volume, has a small dynamic range, and can measure only one protein at a time.	
Here we show a multiplex immunoassay in which three cardiac proteins can be measured simultaneously with high sensitivity. Measuring cMyBP-C in uniplex or together with creatine kinase MB and cardiac troponin I showed comparable sensitivity. This technique uses the Meso Scale Discovery (MSD) method of multiplexing in a 96-well plate combined with electrochemiluminescence for detection. While only small sample volumes are required, high sensitivity and a large dynamic range are achieved. Using this technique, we measured cMyBP-C, creatine kinase MB, and cardiac troponin I levels in serum samples from 16 subjects with MI and compared the results with 16 control subjects. We were able to detect all three markers in these samples and found all three biomarkers to be increased after MI. This technique is, therefore, suitable for the sensitive detection of cardiac biomarkers in serum samples.

The basic principles and workflow of the 3-plex assay are shown in Figure 1, and the overall workflow is described in Table 1. Uniplex assays work along the same principle except that the entire bottom well is coated with one capture antibody. Signal detection is done by ECL in which an electrical signal is applied to the bottom of the well. This, in turn, initiates a local production of light through a chemical reaction of the read-buffer with the SULFO-TAG label on the detection antibo...

Watch this Scientific Journal Video about A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay at JoVE.com

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Measuring biomarkers in complex biological samples is increasingly guiding clinical decision-making. We describe a highly sensitive method to simultaneously measure cardiac myosin binding protein-C, creatine kinase MB, and cardiac troponin I in serum samples from subjects with myocardial infarction and healthy control subjects.

Biomarkers are becoming increasingly more  important in clinical decision-making, as well as basic science. Diagnosing  myocardial infarction (MI) is ...

a-sensitive-specific-quantitation-method-for-determination-serum

Research

JoVE Journal

Biology

16.6K visualizações.  Loyola University Chicago. Biomarcadores de medição em amostras biológicas complexas é cada vez mais guiando tomada de decisão clínica. Nós descrevemos um método altamente sensível para medir simultaneamente miosina cardíaca binding protein-C, MB da creatina quinase e troponina I em amostras de soro de pacientes com infarto do miocárdio e controle de indivíduos saudáveis.

Vídeo: A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay